Previous 10 | Next 10 |
home / stock / kaltf / kaltf news
SAN FRANCISCO and TORONTO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that the journal Scientific Reports, has published a peer-reviewed article reporting that R-107, t...
Claritas Pharmaceuticals (OTCPK:KALTF) announced it has ended its partnership with CMAX Clinical Research for a Phase 1 study on R-107, the company’s experimental liquid, nitric oxide-releasing compound. The company has inked a clinical trial research agreement with Australia-based Sci...
SAN FRANCISCO and TORONTO, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today provided an update regarding the expected time to completion of its Phase 1 clinical study of R-107, the Company...
SAN FRANCISCO and TORONTO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: CLAS.V) (the " Company " or " Claritas ") today announced the engagement of B. Riley Securities, Inc. ( “B. Riley Securities” ) as its exclusive ...
SAN FRANCISCO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: CLAS.V) (the " Company " or " Claritas ") is pleased to announce that it has closed the first tranche of a private placement offering (the “ Offering ”) of c...
SAN FRANCISCO and TORONTO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: CLAS.V) (the " Company " or " Claritas ") today announced that it has entered into a binding Letter of Intent (the “LOI” ) with Biozeus Biopharm...
SAN FRANCISCO and TORONTO, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTD) (the " Company " or " Claritas ") is pleased to announce that, subject to TSXV approval, it will close the first tranche of a brokered private placement off...
SAN FRANCISCO, July 27, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") announced that it granted stock options on July 23, 2021 to the directors and officers of the Company. The stock options have...
BlackJack3D/E+ via Getty Images Claritas Pharmaceuticals (KALTF) has added ~13.3% in the pre-market after the company announced a recent publication of a study validating its nitric oxide-releasing compound, R-107, as a potential therapy against COVID-19. The study conducted by...
SAN FRANCISCO and TORONTO, July 26, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that a recently published study led by clinicians at Royal Brompton & Harefield NHS Foundation Trust ...
News, Short Squeeze, Breakout and More Instantly...
Kalytera Therapeutics Company Name:
KALTF Stock Symbol:
OTCMKTS Market:
Kalytera Therapeutics Website:
SAN FRANCISCO, CA and TORONTO, ON , Feb. 22, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that it has received comments from the Australian Human Research Ethics Committee (the “...
SAN FRANCISCO, CA and TORONTO, ON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that the Australian Human Research Ethics Committee (HREC) will meet on February 16 th to...
SAN FRANCISCO, CA and TORONTO, ON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “ Company ” or “ Claritas ”) today announced revised, improved pricing for the initial tranche of funds that the Co...